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Abstract: Background 
Chronic plaque psoriasis is the most common type of psoriasis and is 
characterised by redness, thickness and scaling. First line management is 
with topical treatments. 
Objective 
To undertake a Cochrane review of topical treatments for chronic plaque 
psoriasis 
Methods 
We systematically searched major databases for randomized controlled 
trials. Trials reported improvement using a range of related measures; 
standardised, pooled findings were translated onto a 6-point improvement 
scale.   
Results 
The review included 177 randomised controlled trials with 34,808 
participants, including 26 trials of scalp psoriasis and six trials of 
inverse and/or facial psoriasis.  Typical trial duration was 3-8 weeks. 
When compared to placebo (emollient base), the average improvement for 
vitamin D analogues and potent corticosteroids was approximately 1 point, 
dithranol 1.2 points, very potent corticosteroids 1.8 points and combined 
vitamin D analogue plus steroid 1.4 points once-daily and 2.2 points 
twice-daily.  However, these are indicative benefits drawn from 
heterogeneous trial findings.  Corticosteroids were more effective than 
vitamin D for treating psoriasis of the scalp.  For both body and scalp 
psoriasis, potent corticosteroids were less likely than vitamin D to 
cause skin irritation.  
Limitations 
Reporting of benefits, adverse effects, and safety assessment methods was 
often inadequate. In many comparisons, heterogeneity made the size of 
treatment benefit uncertain. 
Conclusions 
Corticosteroids are as effective as vitamin D analogues and cause less 
skin irritation. However, further research is needed to inform long-term 
maintenance treatment and provide appropriate safety data. 
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Capsule summary 
· Chronic plaque psoriasis is the most common type of psoriasis and is characterised by 
redness, thickness and scaling. First line management is with topical treatments 
· On a six-point improvement scale, topical therapies provide an additional benefit over 
placebo (emollient) of between 1.0 and 2.2 points.  Corticosteroids are as effective as 
vitamin D analogues and cause less skin irritation 
· We need more research to inform long-term maintenance treatment and provide 
appropriate safety data. 
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Abstract 1 
Background 2 
Chronic plaque psoriasis is the most common type of psoriasis and is characterised by redness, 3 
thickness and scaling. First line management is with topical treatments. 4 
Objective 5 
To undertake a Cochrane review of topical treatments for chronic plaque psoriasis 6 
Methods 7 
We systematically searched major databases for randomized controlled trials. One author extracted 8 
study data and assessed study quality. A second author checked these data. Trials reported 9 
improvement using a range of related measures; standardised, pooled findings were translated onto 10 
a 6-point improvement scale.   11 
Results 12 
The review included 177 randomised controlled trials with 34,808 participants, including 26 trials of 13 
scalp psoriasis and six trials of inverse and/or facial psoriasis.  Typical trial duration was 3-8 weeks. 14 
When compared to placebo (emollient base), the average improvement for vitamin D analogues and 15 
potent corticosteroids was approximately 1 point, dithranol 1.2 points, very potent corticosteroids 16 
1.8 points and combined vitamin D analogue plus steroid 1.4 points once-daily and 2.2 points twice-17 
daily.  However, these are indicative benefits drawn from heterogeneous trial findings.  18 
Corticosteroids were more effective than vitamin D for treating psoriasis of the scalp.  For both body 19 
and scalp psoriasis, potent corticosteroids were less likely than vitamin D to cause skin irritation.  20 
Limitations 21 
Reporting of benefits, adverse effects, and safety assessment methods was often inadequate. In 22 
many comparisons, heterogeneity made the size of treatment benefit uncertain. 23 
Conclusions 24 
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Corticosteroids are as effective as vitamin D analogues and cause less skin irritation. However, 25 
further research is needed to inform long-term maintenance treatment and provide appropriate 26 
safety data. 27 
 28 
Key words: Psoriasis; Review; Drug Administration, Topical; Treatment Outcome; Drug Safety 29 
 30 
  31 
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Abbreviations 32 
CI: confidence interval 33 
IAGI: Investigator’s assessment of global improvement 34 
NSAID: non-steroidal anti-inflammatory drug 35 
RD: risk difference 36 
SMD: standardised mean difference 37 
TNFα: tumour necrosis factor alpha 38 
VDR:  vitamin D receptor 39 
VDRE: vitamin D responsive element 40 
 41 
 42 
  43 
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Background  44 
Psoriasis is a chronic inflammatory skin disease with a prevalence ranging from between 1 and 2% in 45 
the UK and northern European populations1 2 to 0.1 to 0.3% in the Far East3 and China.4 Chronic 46 
plaque psoriasis accounts for 90% of psoriasis cases,5 and most commonly affects the knees, elbows, 47 
lower back and scalp.  It is characterised by red patches of thickened skin (plaques) covered in silver 48 
scales. There is a wide spectrum of disease severity from single plaque to more than 90% of the skin 49 
surface. Psoriasis can lead to social isolation,6 stigmatisation7 and adversely affect the quality of daily 50 
life.8-15 51 
The way that psoriasis develops is complicated and appears to be influenced by many factors 52 
including genetic changes, local trauma, infections, certain drugs (e.g. beta-blockers), endocrine 53 
factors, sunlight, alcohol, smoking and stress.16 Psoriasis skin lesions are characterised by epidermal 54 
hyperproliferation, abnormal keratinocyte differentiation and a lymphocyte inflammatory 55 
infiltrate.17-19 Psoriasis is recognised as an immune-mediated disorder, with tumour necrosis factor 56 
alpha (TNFα), dendritic cells and T-cells all contributing to its pathogenesis.20  A meta-analysis of 57 
three genome-wide association studies (GWAS) has identified 15 new susceptibility loci for 58 
psoriasis,21 bringing the total number of loci associated with psoriasis to 36.  59 
Topical treatments include most prominently vitamin D analogues and topical corticosteroids but 60 
also tar-based preparations, dithranol, salicylic acid and topical retinoids.16 As there is no strong 61 
evidence-base on which to consistently sequence topical treatments,17 treatment should be tailored 62 
to individual need.18 19  Emollients are generally used in addition to topical treatments, to normalise 63 
hyperproliferation, differentiation, and to exert anti-inflammatory effects.20 64 
This paper is based on a Cochrane review most recently substantially amended in The Cochrane 65 
Library 2013, Issue (to follow3) (see http://www.thecochranelibrary.com).21 Cochrane reviews are 66 
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regularly updated as new evidence emerges and in response to feedback, and The Cochrane Library 67 
should be consulted for the most recent version of the review. 68 
Objective 69 
To compare the effectiveness, tolerability and safety of topical treatments for chronic plaque 70 
psoriasis, relative to placebo;  to compare vitamin D analogues with other topical treatments. 71 
Methods 72 
Inclusion criteria 73 
We included randomised controlled trials in the review. Trials could be either placebo-controlled or 74 
head-to-head with a vitamin D preparation (head-to-head trials compare active treatments with 75 
each other). Trials of systemic or ultra-violet (phototherapy) treatments with adjunctive topical 76 
treatment were not eligible for inclusion.  For within-patient studies, we included only those studies 77 
that clearly adopted a left-right design and excluded studies where multiple plaques are treated with 78 
more than two products.  If no useful useable effectiveness, withdrawal or adverse events data were 79 
available, either from the published paper or from sponsors or triallists, we excluded the study.  80 
Data extraction 81 
One author extracted study data and assessed study quality. A second author checked these data. 82 
Searches 83 
Table 1 shows the electronic databases searched.  Ongoing studies were identified from the UK 84 
Clinical Research Network Study Portfolio and the metaRegister of Current Controlled Trials. We 85 
routinely contacted triallists and companies for missing data.  86 
 87 
TABLE 1 HERE 88 
 89 
Outcomes 90 
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We extracted data from trials on the four primary outcomes (Table 2). Trials often reported more 91 
than one measure, but no measure was reported by all trials. We therefore devised a 'combined 92 
endpoint', which to facilitated treatment comparisons. Our review summary focused on this 93 
measure.  We constructed the combined endpoint by taking primary outcomes data in the following 94 
order listed in Table 2, according to availability: investigator global assessment; total severity score; 95 
PASI; patient global assessment (see Table 2 for definitions). We analysed findings in RevMan 5.222 96 
using a standardised mean difference (SMD) statistic in a random effects model.  The SMD is the 97 
difference between the means (value for the intervention group less value for the comparator 98 
group), divided by the pooled standard deviation.  The SMD is therefore ‘unit-neutral’, i.e. 99 
independent of the scale used for measurement.  This approach is therefore valid for the 100 
comparison of different outcome measures, provided that they are all essentially assessing the same 101 
characteristics: redness, thickness and scaling.  An alternative approach is to use binary outcomes 102 
such as success rates, but this approach imposes an additional assumption that the cut-off for 103 
‘success’ is constant across outcomes; dichotomisation of continuous scales is also an inefficient use 104 
of information.   Where studies did not report estimates of variance, we derived them from 105 
confidence intervals or from P values where possible, or imputed them deterministically by pooling 106 
the standard deviations of treatment cohorts fully reported in trials and adjusted for scale. These 107 
pooled statistics were used to translate the combined endpoint back to natural units on a 6-point 108 
investigator’s improvement scale (see Table 2).  For example, if an average patient achieves a ‘mild’ 109 
improvement with placebo, but a ‘moderate’ (or ‘marked’) improvement with the active treatment, 110 
this is equivalent to a one point (two point) improvement.   111 
We extracted data on five secondary outcomes: data on withdrawal due to any cause, to adverse 112 
events and to treatment failure, as well as a count of individuals experiencing adverse events due to 113 
local (cutaneous) and systemic effects (e.g. hypercalcaemia). As definitions of withdrawal and 114 
adverse events vary between trials, data were summarised using a random effects risk difference 115 
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(RD) metric.  Heterogeneity (inconsistency between studies) was assessed using the I-squared 116 
statistic, which is the percentage of the variability in effect estimates from the different subgroupsin 117 
a meta analysis that is due to genuine subgroup differences rather than sampling error (chance).23 118 
TABLE 2 HERE 119 
 120 
Structure of the review 121 
The Cochrane review grouped data into 19 comparisons.  These cover placebo-controlled trials of 122 
the body (comparisons 1-6); head-to-head trials of the body (comparisons 7-15); trials of inverse 123 
psoriasis (psoriasis affecting the folds of the skin) or facial psoriasis (comparisons 16 and 17); and 124 
trials of scalp psoriasis (comparisons 18 and 19).   125 
 126 
  127 
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Results 128 
The review included 177 randomised controlled trials, including 26 trials of scalp psoriasis and six 129 
trials of inverse and/or facial psoriasis.  The oldest trial was published in 1975 and the most recent in 130 
2011.   131 
 132 
There were 106 placebo controlled trials, 84 compared treatments directly (head-to-head), with 13 133 
trials reporting both placebo-controlled and active comparisons.  The trials included 34,808 134 
participants, with a mean age of 47 (range: 2 to 97) and a higher proportion of men (57%).  135 
Treatment duration was 7 weeks on average, but this ranged from one week to 52 weeks.  As a 136 
marker of study quality, 74% of the trials were double-blind.  Single-blind (investigator only) and 137 
'open' (no blinding) trials were typically those in which it was impossible to conceal the identity of 138 
investigated products from patients (e.g. coal tar, dithranol, or products using different vehicle 139 
formulations such as cream vs. ointment).  Forty-seven trials (27%) clearly reported the 140 
randomisation method, and concealment of treatment allocation was considered ‘adequate’ in 15 141 
trials (9%).  142 
 143 
Placebo-controlled trials of body psoriasis (comparisons 1-6) 144 
Most treatments for psoriasis of the body were more effective than placebo.  The pooled effect 145 
(SMD) across all vitamin D analogues was -0.90 (95% CI -1.06 to -0.72; 30 studies; 4986 patients; I²: 146 
87.5%), equivalent to 1.0 on a 6-point improvement (IAGI) scale. The average effect was similar for 147 
calcipotriol, calcitriol and tacalcitol while findings for other agents were limited to single trial 148 
reports.  However, there was significant variation in findings of individual trials ranging from 0.1 to 149 
3.6 (an outlier) on a 6-point IAGI scale. 150 
 151 
FIGURE 1 HERE 152 
 153 
10 
 
 
 
Potent topical corticosteroids were similarly effective: in 13 trials with 2216 patients, the pooled 154 
effect across all studies was -0.89 (95% CI -1.06 to -0.72; I²: 65.1%), equivalent to 1.0 on a 6-point 155 
IAGI scale.  However betamethasone dipropionate BD was significantly more effective than 156 
betamethasone dipropionate OD (1.6 vs. 0.9 on a 6-point IAGI scale). Only betamethasone 157 
dipropionate OD and BD, betamethasone valerate and fluticasone propionate provided evidence 158 
from more than one placebo-controlled trial.  159 
 160 
FIGURE 2 HERE 161 
 162 
The pooled effect across 10 trials (1264 patients) of very potent steroids was -1.56 (95% CI -1.87 to -163 
1.26; I²: 81.7%), equivalent to 1.8 on a 6-point IAGI scale. Overall findings were similar for clobetasol 164 
propionate and halobetasol, the only two agents studied, although there was significant variation 165 
between individual trial findings ranging from 1.0 to 2.8 on a 6-point IAGI scale. 166 
 167 
FIGURE 3 HERE 168 
 169 
Of the three placebo-controlled trials of dithranol (covering 47 patients in total), the most recent 170 
was published in 1997.  The SMD for the combined endpoint was -1.06 (95% CI -1.66 to -0.46; I²: 171 
37%), equivalent to 1.2 on a 6-point IAGI scale. There was variation in treatment regimens between 172 
the trials and the effect in individual trials ranged from 0.8 to 1.9 on a 6-point IAGI scale.  173 
 174 
FIGURE 4 HERE 175 
 176 
Combination treatment (vitamin D plus a corticosteroid) was compared with placebo in five trials. 177 
The SMD for the combined endpoint was -1.44 (95% CI -1.76 to -1.12; I²: 93%), although twice-daily 178 
combination treatment (SMD -1.90; 95% CI -2.09 to -1.71) suggested a larger effect than once-daily 179 
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treatment (SMD -1.21; 95% CI -1.50 to -0.91). On a six-point IAGI scale, these equate to 180 
improvements of 2.2 and 1.4 points respectively.  181 
 182 
We also reviewed 26 treatments that did not fit the above categories, including tazarotene (one 183 
trial) which improved psoriasis by one point more than placebo on a six-point IAGI scale, a similar 184 
effect to vitamin D analogues and potent corticosteroids.   185 
 186 
Head-to-head trials of body psoriasis (comparisons 7-15) 187 
Direct (head-to-head) comparisons were made of vitamin D analogues (alone or in combination) 188 
with other treatments.  Fourteen trials compared vitamin D analogues directly with potent 189 
corticosteroids (3542 patients). Although there was no significant difference between the two 190 
groups of drug, substantial heterogeneity underlay this finding. Over 80% of patients were recruited 191 
into seven trials.  Three trials comparing calcipotriol with betamethasone dipropionate found the 192 
steroid to be more effective (SMD 0.43; 95% CI 0.28 to 0.58, I2=50%) or 0.5 points on a six-point IAGI 193 
scale, while four trials comparing calcipotriol  with betamethasone valerate found no difference 194 
(SMD -0.12; 95% CI -0.26 to 0.02, I2=42%). 195 
 196 
The comparison of vitamin D against very potent steroids found no significant difference between 197 
calcipotriol and clobetasol propionate (SMD -0.06; 95% CI -0.57 to 0.44, I2=26%), a finding based on 198 
two small trials and only 82 patients.   199 
 200 
Combination therapy (vitamin D plus corticosteroid) was more effective than either individual 201 
product used as monotherapy.  Most information related to calcipotriol and betamethasone 202 
dipropionate including 76% of patients. Calcipotriol combined with betamethasone dipropionate 203 
was more effective than calcipotriol alone (SMD -0.57 95%CI: -0.42, -0.72, I2=81%), and calcipotriol 204 
combined with betamethasone dipropionate was more effective than betamethasone dipropionate 205 
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alone (SMD -0.40 95%CI: -0.52, -0.27, I
2
=42%).  These changes equate to approximately 0.6 and 0.4 206 
points respectively on a six-point IAGI scale. 207 
 208 
Findings on the comparison of dithranol against vitamin D were highly heterogeneous (I2=95%), 209 
possibly reflecting variation in the dithranol regimens employed by trials and in the baseline severity 210 
of trial participants.   211 
 212 
Trials of inverse or facial psoriasis (comparisons 16-17) 213 
There were 2 small placebo-controlled trials of three agents and only 122 patients in total. These 214 
provided tentative evidence in favour of betamethasone valerate, calcipotriol and the topical 215 
calcineurin inhibitor pimecrolimus (by 3.25, 1.2 and 1.0 points on a six-point scale).   There were four 216 
head-to-head trials (588 patients) involving vitamin D analogues each comparing different agents.  217 
Of these 408 (70%) of patients were recruited to one trial comparing calcipotriol and hydrocortisone 218 
with calcipotriol: combination treatment was more effective (SMD -0.30 95%CI: -0.11 to -0.50).   219 
 220 
Trials of scalp psoriasis (comparisons 18-19) 221 
We identified 14 placebo-controlled trials in scalp psoriasis involving 3011 patients. Most evidence 222 
concerned four comparisons.  Calcipotriol (SMD -0.72, 95%CI: -1.28 to -0.16, I2=69%) delivered 0.9 223 
points improvement; betamethasone dipropionate (SMD: -1.09, 95%CI: -1.29 to -0.90, I2=0%) 224 
delivered 1.3 points improvement; clobetasol propionate (SMD -1.57, 95%CI: -1.81 to -1.34; I²: 225 
43.3%) delivered 1.9 points; while calcipotriol and betamethasone dipropionate combined (I2=90%) 226 
varied from 0.7 to 1.5 points, possibly reflecting the ethnically different patient populations.24 25  227 
 228 
In 5 head-to-head trials (2337 patients), vitamin D was consistently less effective than potent or very 229 
potent corticosteroids (SMD: 0.45, 95%CI: 0.36 to 0.53, I2=1%) equating to 0.6 points on a six-point 230 
IAGI scale. Monotherapy with vitamin D was consistently less effective than vitamin D combined 231 
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with potent corticosteroids (4 trials, 2581 patients) although findings were heterogeneous I
2
=82%) 232 
ranging between 0.5 and 1.2 points on a six-point IAGI scale.   Combination therapy was more 233 
effective than potent steroids alone (SMD: -0.18, 95%CI: -0.26 to -0.10, I2=0%) equating to 0.2 234 
points.  There was no overall significant difference between calcipotriol and coal tar polytherapy 235 
although findings were heterogeneous (3 trials, 835 patients, I2=90%).  236 
 237 
Adverse events 238 
We summarised data on the rate of systemic adverse events (those occurring within the body) and 239 
the rate of local (cutaneous) adverse events such as skin irritation.  Of the vitamin D analogues, most 240 
data were available for calcipotriol. Used on the body, calcipotriol monotherapy was associated with 241 
a significantly higher rate of local adverse events than potent steroids (I2=80%, range of the 242 
individual studies from 6% to 22%) or combination therapy of calcipotriol plus steroid (RD 6%, 243 
95%CI: 4% to 8%, I2=9%).   244 
Similarly, used on the scalp, calcipotriol monotherapy was associated with a significantly higher rate 245 
of local adverse events than steroids (I2=78%, range from 7% to 24%) or combination therapy of 246 
calcipotriol plus potent steroid (RD 9%, 95%CI: 6% to 12%, I2=28%).  However, when used on the 247 
body calcipotriol was associated with a significantly lower rate of local adverse events than dithranol 248 
(RD -25%, 95%CI: -32% to -17%, I2=51%). Comparative data for other agents was limited. No trial 249 
found a significant difference in the rate of systemic adverse events.   250 
 251 
Conclusions 252 
Evidence from large numbers of trials indicates that most topical treatments alleviate the symptoms 253 
of psoriasis.  While trial evidence is considerable for vitamin D analogues and steroids alone or in 254 
combination and for dithranol, the evidence for a large number of other agents is inadequate and 255 
often limited to single small trials.  There is also an increasing evidence base for long-term 256 
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maintenance regimes which vary in frequency and dose and so are difficult to summarise.  Details of 257 
these maintenance regimes and less-researched regimes are reported in the Cochrane review.  258 
 259 
On average, when compared to placebo (emollient base) vitamin D analogues and potent steroids 260 
may achieve an approximate 1 point gain on a 6 point improvement scale, dithranol 1.2 points, very 261 
potent corticosteroids 1.8 points, and combined vitamin D analogue plus steroid 1.4 points once-262 
daily and 2.2 points twice daily.  However these indicative benefits should be viewed with caution as 263 
they are drawn from heterogeneous trial findings.  264 
 265 
Although vitamin D analogues and corticosteroids are equally effective for treating psoriasis of the 266 
body, corticosteroids appear to be more effective than vitamin D for treating psoriasis of the scalp. 267 
Combined treatment of vitamin D with corticosteroid appears to have a small additional benefit 268 
above vitamin D alone or corticosteroid treatment alone.  269 
 270 
The reporting of trials prohibited adequate exploration of the potential causes of heterogeneity. For 271 
example, treatment performance may be affected by disease severity, though poor reporting of 272 
baseline severity in trials meant this could not be confirmed.  Adherence may also be enhanced 273 
when using a combined product, if application time is shorter.  274 
 275 
Potent corticosteroids are less likely than vitamin D to cause local adverse events. Our review found 276 
no difference between placebo and any topical treatment in the assessment of systemic adverse 277 
events. However, this may reflect an absence of evidence (trials failing to appropriately assess these 278 
events over adequate time periods) rather than being evidence of absence.  279 
 280 
Although current evidence demonstrates that topical steroids are as effective as and at least as well 281 
tolerated as vitamin D analogues, concern remains about the potential safety problems associated 282 
15 
 
 
 
with corticosteroids.
26
 Concerns include the risk of rebound (a worsening of disease following 283 
treatment discontinuation), skin atrophy (skin thinning) and tachyphylaxis (decreasing response to 284 
the drug) after long-term use.27 Methods to assess rebound have been developed and should be 285 
used in future research.28 Regarding skin thinning, one problem with psoriasis is that the skin is very 286 
thick and a goal of therapy is to reduce the thickness of lesional (epidermal) skin.  The issue may 287 
become a historical one, if newer safer steroids, currently being developed and evaluated for atopic 288 
dermatitis, subsequently demonstrate efficacy and safety in chronic plaque psoriasis. 289 
  290 
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Rank
1
 Primary Outcome measures Construct 
1 Investigator Assessment of Global 
Improvement;
2
 
or the equivalent static score, 
Investigator Global Assessment of 
Disease Severity 
Improvement from baseline, usually scaled from 
worse to cleared; higher scores indicate greater 
improvement. 
Disease severity usually scaled from ‘absence of 
disease’ to ‘very severe disease’; higher scores 
indicate more severe disease. 
2 Total Severity Score Redness (erythema), thickness (infiltration) and 
scaling (sometimes also itching (pruritis)) of 
target plaque(s). Scored separately then 
summed. 
3 Psoriasis Area Severity Index (PASI) Redness, thickness, and scaliness of the lesions 
(each graded on a 0 to 4 scale), weighted by the 
area of involvement (0 to 6) and summed.  
Scored from 0 to 72 (if head excluded: 0 to 68) 
4 Patient (or Subject) Assessment of Global 
Improvement;
2
 or the equivalent static 
score, Patient (or Subject) Global 
Assessment of Disease Severity 
See Investigator Assessment of Global 
Improvement 
 
1 
Order for inclusion in ‘combined endpoint’ 
2
 Global improvement data are entered as a negative values, thus a reduction denotes a positive 
improvement for the active treatment consistent with other measures. 
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